Media Release


Roche's Evrysdi (Risdiplam) - the first and only oral treatment for adults and children two months or older suffering from Spinal Muscular Atrophy (SMA) now available in India.

Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India

Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19

Company statement on Tocilizumab (Brand: Actemra) supplies

US-FDA Approved Foundation Medicine's foundationone®Liquid cdx, a Pan-Tumor Liquid Biopsy Genomic Test for Late Stage Cancer Patients now Available in India

Roche Pharma India expands partnership with Cipla to further improve access to key oncology medicines

Roche Pharma India partners with Entero Healthcare Solutions to improve access to nephrology medicines

V. Simpson Emmanuel appointed as General Manager, Roche Products (India) Pvt. Ltd.

Roche’s Atezolizumab receives DCGI approval for treatment of metastatic triple-negative breast cancer in India

Roche’s Atezolizumab receives DCGI approval for treatment of extensive-stage small cell lung cancer in India

Roche launches new therapy Emicizumab for people with Hemophilia A on World Hemophilia Day

Roche and St. Jude India ChildCare Centre come together with Dr. B Barooah Cancer Institute to offer holistic cancer care to underprivileged children

Roche Pharma India partners with Cipla to create greater access to key medicines

Providing confidence and support to patients
Roche India’s "The Blue Tree" program offers support to cancer patients during their treatment journey, from diagnosis till completion of therapy.It is a patient support initiative that is designed to take care of the multiple hurdles that a patient has to go through during the course of receiving treatment.  Read more

Approval of biosimilars must be subject to rigorous clinical and regulatory standards.
In order to ensure patients and physicians can make informed treatment decisions, it is critical that they have full access to information about products claiming to be similar to or a biosimilar of innovative biologics, and clarity on whether or not they have met the requirements for biosimilar products. Read more

Company Statement: Delhi High Court Interim Order, March 03, 2017